Patient characteristics
| Purulent exacerbations | Mucoid exacerbations | ||||
|---|---|---|---|---|---|
| Demographic data | 5 days cefuroxime | 10 days cefuroxime | Fluticasone | Placebo | |
| Age | 66.1 (8.0) | 65.9 (10.3) | 65.2 (6.5) | 59.5 (8.9) | |
| M/F | 12/9 | 13/6 | 6/7 | 6/4 | |
| Current(ex) smokers | 9 (12) | 8 (11) | 8 (5) | 8 (2) | |
| FEV1 pre bronchodilator (% predicted) | 55.3 (19.6) | 67.4 (27.5) | 63.8 (28.3) | 70.0 (22.0) | |
| FEV1/VC pre bronchodilator (%) | 46.6 (14.7) | 56.8 (17.6) | 51.0 (18.9) | 56.8 (18.9) | |
| Increase in FEV1 after salbutamol (l) | 0.15 (0.14) | 0.19 (0.13) | 0.19 (0.13) | 0.17 (0.12) | |
Values are mean (SD).
There were no significant differences between any of the subgroups studied.